Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study
ConclusionAcknowledging RA patients ’ perceived barriers to influenza and pneumococcal vaccination and implementing specific strategies to address them might increase vaccination coverage in this population. (Source: Rheumatology)
Source: Rheumatology - June 4, 2021 Category: Rheumatology Source Type: research
Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom
ConclusionThe evidence available on the burden of moderate RA is limited. Despite current treatments, moderate RA still has a substantial negative impact, given that a DAS28 disease activity score defined as being in the moderate range does not qualify them for access to advanced therapies in the United Kingdom. For these patients, there is a particular need for further studies that investigate their burden and the impact of treating them earlier. Such information would help guide future treatment decisions and ensure the most effective use of resources to gain the best outcomes for patients with moderate RA. (Source: Rheumatology)
Source: Rheumatology - June 3, 2021 Category: Rheumatology Source Type: research
Cross-reactive anti-CENP-A autoantibodies induce analytic interference in anti-TIF1 γ detection using line-dot immunoassay
Dear Editor, Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases, characterized by inflammatory cell infiltrates in muscle tissue. They usually manifest as muscle weakness but can also be associated with extra-muscular manifestations [1]. Myositis-specific autoantibodies (MSA) play a key role in diagnosis and are increasingly recognized as important tools for the classification, management and prognosis of IIM. At present, different techniques exist to detect the presence of MSA in the serum of patients. Immunoprecipitation is considered as the gold standard for most autoantibodies but...
Source: Rheumatology - May 22, 2021 Category: Rheumatology Source Type: research
Comment on: Refining myositis associated with primary Sj ögren’s syndrome: data from the prospective cohort ASSESS
(Source: Rheumatology)
Source: Rheumatology - May 19, 2021 Category: Rheumatology Source Type: research
Comment on: Hematological malignancies in giant cell arteritis: a French population-based study
Dear Editor, We read with interest the article by Greigertet al., published recently inRheumatology [1]. The authors conducting a population-based study on the association of haematological malignancies (HM) and GCA found an overall frequency of 4.3% and an increased frequency of myeloid HM (standardized incidence ratio, SIR =2.71), especially myeloproliferative syndromes (MPS, SIR =5.16), with a specific increase in men with GCA but not in women. Additionally, there was a risk of developing GCA in men, after a diagnosis of myeloid HM (SIR =9.56), especially if it was a MPS (SIR =17.56). We had published a single-centre ...
Source: Rheumatology - May 16, 2021 Category: Rheumatology Source Type: research
Empathic communication during a pandemic: How can we minimize the deficit?
Communication is essential to the management of all chronic diseases including those treated by rheumatologists. To help the patient manage their disease, they need to achieve several things: sufficient understanding of the disease, the pros and cons of different possible interventions and how best to self-manage the disease, including how to cope with flares and when to ask for help. Communication is complex even when all modalities are available, but is severely diminished when done remotely, even with video, as we are all now learning during the COVID-19 pandemic. (Source: Rheumatology)
Source: Rheumatology - May 14, 2021 Category: Rheumatology Source Type: research
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
ConclusionsIn this NMA, guselkumab demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous TNF inhibitors while offering better PASI response relative to many other treatments. (Source: Rheumatology)
Source: Rheumatology - May 14, 2021 Category: Rheumatology Source Type: research
A rare manifestation of sensory neuropathy in primary Sj ögren syndrome
Dear Editor, Peripheral neuropathy is a major neurological manifestation in Primary Sj ögren’s syndrome (PSS), but sensory ganglioneuronitis is an infrequent presentation with no validated treatment strategy. Furthermore, the trigeminal trophic syndrome (TTS) is a rare disease not reported before in PSS. (Source: Rheumatology)
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
The scleromyositis phenotype. Lessons from a multicentre international cohort of anti-PM/Scl –positive patients
SSc and myositis are well-recognized neighbours, and in some cases the clinical features of the two disorders overlap, as occurs in patients with a unique antibody, anti-PM/Scl, in a condition known as scleromyositis. In addition, myositis and SSc patients can have a similar genetic background [1]. This may explain why some patients with antisynthetase syndrome —an overlap myositis syndrome characterized by coexistence of myositis, interstitial lung disease and arthritis—and antibodies against several t-RNA synthetases can resemble patients with scleromyositis, specifically those with anti-PM/Scl antibodies [2]. (Source: Rheumatology)
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases
This study may serve as a basis for improved communication and thus help increase COVID-19 vaccine coverage among AIIRD patients. (Source: Rheumatology)
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
Comorbidities (excluding lymphoma) in Sj ögren’s syndrome
AbstractThe information about comorbidities (excluding lymphoma) in primary Sj ögren’s syndrome (pSS) is relatively scarce. Cardiovascular disease, infections, musculoskeletal conditions or malignancy are likely the most relevant comorbid conditions in pSS. Different infections (particularly oral candidal infections) and fibromyalgia are extremely frequent in the daily clin ical practice. On the other hand, the incidence of cardiovascular events and cancer in pSS is low, so information about them comes from large epidemiological studies or meta-analysis. For this reason, preclinical vascular disease is investigated by d...
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
Genetics and epigenetics in primary Sj ögren’s syndrome
This article reviews the hitherto published genetic studies and our current understanding of epigenetic mechanisms in pSS. (Source: Rheumatology)
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
Treatment of Sj ögren’s syndrome: current therapy and future directions
AbstractSS is usually described as having severe fatigue, dryness, diffuse pain, glandular swelling, and various extraglandular (systemic) manifestations. Clinical trials have generally failed because the vast majority of enrolled patients had no extraglandular manifestations at the time of enrolment but suffered from fatigue, dryness and pain that did not significantly respond to the study medication. A number of hypotheses on the pathogenesis of pSS have been put forward, including disturbances of innate and adaptive immunity as well as abnormalities of the interface between immune disorders and the neuro-endocrine syste...
Source: Rheumatology - May 13, 2021 Category: Rheumatology Source Type: research
Multisystem inflammatory syndrome in an adult with involvement of the skin, lymph nodes, muscle, heart, liver and kidneys
Rheumatology key messageMIS-A is a new disease in rheumatology that providers must learn to diagnose and treat. (Source: Rheumatology)
Source: Rheumatology - May 12, 2021 Category: Rheumatology Source Type: research
Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis
In this issue ofRheumatology, Fleischmannet al. [1] published the 5 year follow-up results of the EXTEND trial (NCT01146652), in which long-standing RA patients with an inadequate response or intolerance (IR) to TNF inhibitors (TNFis) received sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs (csDMARDs). This is the open-label extension (OLE) of the TARGET trial (NCT01709578) in which sarilumab 150 or 200 mg every 2 weeks plus csDMARDs was compared with placebo plus csDMARDs in the same population. Most patients discontinued prior anti-TNF therapy because of an inadequate response (92.3%), thus T...
Source: Rheumatology - May 11, 2021 Category: Rheumatology Source Type: research
